Skip to main content

Table 1 p53 mutation status and prevalence.

From: Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

p53 status

Rules

Prevalence (%)

N = 520

Wild-type p53

No variation*; synonymous variations; intronic variations outside splice sites

435 (83.6%)

Mutated p53

Any variation predicted to modify protein sequence: missense, nonsense, insertion, deletion, variation in splice sites

85 (16.3%)

Subcategorization of mutated p53

   Missense mutation

Protein changed by one amino acid

64 (12.3%)

   Truncating mutation

Nonsense, insertion**, deletion**, variation in splice sites

19 (3.6%)

   Not classified***

 

2 (0.4%)

  1. Sample classification status is based on the predicted impact of mutation on p53 protein. Only exons 5 to 8 and splicing junctions were sequenced.
  2. *Any nonsynonymous variation in exon 5 to 8. **All insertion and deletion found in this series induced a frameshift.. ***Not subclassified because the sequencing result was missing for one exon.